Boehringer Ingelheim

Asthma Inhaler Costs to Be Slashed as Drugmakers Introduce $35 Price Cap

Asthma Inhaler Costs to Be Slashed as Drugmakers Introduce $35 Price Cap

Many Americans will benefit from reduced inhaler costs as AstraZeneca and Boehringer Ingelheim implement new out-of-pocket price caps of $35 per month, reflecting a move towards more affordable asthma medication following years of public concern over high prices.

Read Full Article

Boehringer Ingelheim may sell U.S. generic unit

German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.

Read Full Article

Actavis, Sanofi among bidders for Omega Pharma

Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.

Read Full Article

Accelrys picks up Irish software firm Qumas in $50M takeover deal

California, US-based software developing company Accelrys has acquired Ireland-based software business Qumas in a deal valued at $50 million to expand its products expansion and client base.

Read Full Article

Boehringer subsidiary hires Bank of America to explore sale of injectable drugs business

Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.

Read Full Article

FDA sets standards for good manufacturing compliance for Ben Venue

Ben Venue was required by court to comply with good manufacturing standards set.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics